Boehringer, Zealand's survodutide shows no added heart risk in Phase 3 CV safety trial
- In the Phase 3 SYNCHRONIZE-CVOT trial (5,530 adults with overweight or obesity and elevated cardiovascular risk), survodutide was non-inferior to placebo on major cardiovascular events.
- Results were presented at AHA and published in The Lancet; at 72 weeks it also lowered systolic blood pressure and waist circumference versus placebo.
- GI-related discontinuations ran about 19-21% versus 1.9% on placebo; Zealand attributes this to limited titration flexibility, and analysts flag tolerability as a liability.
- The data support global regulatory filings for obesity.
💡 Points Based on public reports
Clearing the CV safety bar de-risks filing, but survodutide arrives behind semaglutide and tirzepatide with GI discontinuations near 20%, which is hard to defend commercially. Its real differentiation is glucagon-driven liver benefit; the MASH data and any gentler titration results will decide whether it is a contender or a follower.
Boehringer, Zealand's obesity drug doesn't elevate heart risk in key late-stage test ↗